<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> (L-OHP), a <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-containing <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> agent, is a key drug for the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, it is often difficult to continue with its treatment because of the expression of allergic reactions </plain></SENT>
<SENT sid="2" pm="."><plain>This study was an investigation of the expression of allergic reactions resulting from administration of L-OHP </plain></SENT>
<SENT sid="3" pm="."><plain>A retrospective analysis was performed on patients undergoing therapeutic regimens including L-OHP, from April 2009 to November 2010 in Juntendo University Urayasu Hospital </plain></SENT>
<SENT sid="4" pm="."><plain>The results showed that allergic reactions were expressed in 15 out of 81 patients (18 </plain></SENT>
<SENT sid="5" pm="."><plain>5%) </plain></SENT>
<SENT sid="6" pm="."><plain>A high correlation was found between the time from administration until expression of the allergic reaction, and the number of treatment courses (r=-0 </plain></SENT>
<SENT sid="7" pm="."><plain>521, p=0 </plain></SENT>
<SENT sid="8" pm="."><plain>047) </plain></SENT>
<SENT sid="9" pm="."><plain>When patient characteristics were compared between the allergic reaction group and the no-reaction group, it was suggested that differences due to the regimen or the presence or absence of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, which is considered to be related to drug metabolism, had no effect </plain></SENT>
<SENT sid="10" pm="."><plain>Items showing significant differences were sexual difference(p=0 </plain></SENT>
<SENT sid="11" pm="."><plain>022)and the effect of changes depending on the dose form of L-OHP(p=0 </plain></SENT>
<SENT sid="12" pm="."><plain>003) </plain></SENT>
<SENT sid="13" pm="."><plain>It was possible to continue treatment with L-OHP in six patients even after expression of allergic reactions </plain></SENT>
<SENT sid="14" pm="."><plain>Anti-<z:e sem="disease" ids="C0869403,C0700625,C0020517" disease_type="Pathologic Function;Disease or Syndrome" abbrv="">allergy</z:e> measures such as additional administration of steroids or <z:chebi fb="5" ids="37956">antihistamines</z:chebi> were suggested to be useful for continuing treatment </plain></SENT>
</text></document>